Dapagliflozin reduces cardiovascular death risk in patients with preserved ejection fraction EP News Bureau Sep 7, 2022 Results were presented at European Society of Cardiology Congress 2022, and published in 'New England Journal of Medicine'
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust… EP News Bureau Nov 19, 2021 Six months' follow-up of prevention trial showed 83 per cent reduced risk of symptomatic COVID-19, with no severe disease or…
